Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECARDO study of docetaxel + carboplatin versus docetaxel in docetaxel-sensitive castration-resistant prostate cancer
NL-OMON35127Phase 2Recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Feb 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, carboplatin and prednisone in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Progression-free survival. Started Feb 2010; status: recruiting.
02
Drugs
docetaxelcarboplatinprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON35127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35127.